Abstract:Background: Phase III study of short-term radiotherapy followed by neoadjuvant chemotherapy versus preoperative long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR trial) How to optimize preoperative treatment regimens for locally advanced rectal cancer (LARC) is the focus of recent studies, The purpose of STELLAR trial is to compare short course radiotherapy (SCRT) followed by neoadjuvant chemotherapy (NACT) with preoperative chemoradiotherapy (CRT) in patients with LARC.Trial design: The purpose of the STELLAR trial is to compare effectiveness of short course radiotherapy (SCRT) followed by neoadjuvant chemotherapy (NACT) (experimental group) with preoperative long-term chemoradiotherapy (CRT) (control group) in locally advanced rectal cancer (LARC). The hypothesis is 3-year disease-free survival in experimental group was non-inferior to that in control group. STELLAR trial is an open-label, prospective phase III randomized trial. At least five hundred and fifty-two previously untreated patients of stage II/III rectal adenocarcinoma between the age of 18 and 70 will be enrolled and randomized into experimental group or control group. All patients will be provided with written informed consents and cancer staging must be based on pelvic MRI. The primary endpoint is 3-year disease-free survival. In experimental group, patients will receive a SCRT (25 Gy/ 5 fractions/ 5 days), followed by NACTs after 7-10 days of radiotherapy, given in three-week-cycle of capecitabine 1000 mg/m2 twice daily, day 1–14 combined with oxaliplatin 130 mg/m2 day 1. In total, 4 cycles of NACTs are prescribed preoperatively, followed by a TME surgery and postoperative adjuvant chemotherapy. In control group, patients will receive a long-term CRT (50Gy/ 25 fractions/35 days with capecitabine) preoperatively, followed by a TME surgery and then postoperative adjuvant chemotherapy. Capecitabine is given in combination with radiation at a dose of 825 mg/m2 twice daily on radiotherapy days, excluding weekends.Clinical trial identification: NCT02533271Disclosure: All authors have declared no conflicts of interest. Background: Phase III study of short-term radiotherapy followed by neoadjuvant chemotherapy versus preoperative long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR trial) How to optimize preoperative treatment regimens for locally advanced rectal cancer (LARC) is the focus of recent studies, The purpose of STELLAR trial is to compare short course radiotherapy (SCRT) followed by neoadjuvant chemotherapy (NACT) with preoperative chemoradiotherapy (CRT) in patients with LARC. Trial design: The purpose of the STELLAR trial is to compare effectiveness of short course radiotherapy (SCRT) followed by neoadjuvant chemotherapy (NACT) (experimental group) with preoperative long-term chemoradiotherapy (CRT) (control group) in locally advanced rectal cancer (LARC). The hypothesis is 3-year disease-free survival in experimental group was non-inferior to that in control group. STELLAR trial is an open-label, prospective phase III randomized trial. At least five hundred and fifty-two previously untreated patients of stage II/III rectal adenocarcinoma between the age of 18 and 70 will be enrolled and randomized into experimental group or control group. All patients will be provided with written informed consents and cancer staging must be based on pelvic MRI. The primary endpoint is 3-year disease-free survival. In experimental group, patients will receive a SCRT (25 Gy/ 5 fractions/ 5 days), followed by NACTs after 7-10 days of radiotherapy, given in three-week-cycle of capecitabine 1000 mg/m2 twice daily, day 1–14 combined with oxaliplatin 130 mg/m2 day 1. In total, 4 cycles of NACTs are prescribed preoperatively, followed by a TME surgery and postoperative adjuvant chemotherapy. In control group, patients will receive a long-term CRT (50Gy/ 25 fractions/35 days with capecitabine) preoperatively, followed by a TME surgery and then postoperative adjuvant chemotherapy. Capecitabine is given in combination with radiation at a dose of 825 mg/m2 twice daily on radiotherapy days, excluding weekends. Clinical trial identification: NCT02533271 Disclosure: All authors have declared no conflicts of interest.

The Initial Results for a Phase III Study of Short-Term Radiotherapy Plus Chemotherapy Vs Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR Trial).

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports.

235TiPPhase III study of short-term radiotherapy followed by neoadjuvant chemotherapy versus preoperative long-term chemoradiotherapy in locally advanced rectal cancer

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)

Long-term Results of Postoperative Chemoradiation Therapy with Capecitabine and Oxaliplatin Versus Capecitabine Alone for Locally Advanced Rectal Cancer: A Randomized, Multicenter, Phase III Trial.

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Preliminary Results of a Prospective Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial

47P Safety and Efficacy Evaluation of Long-Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer: Intermediate Results of a Multicenter, Phase II Study

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer

Primary surgery followed by selective radiochemotherapy versus conventional preoperative radiochemotherapy for patients with locally advanced rectal cancer with MRI-negative circumferential margin (PSSR): A multicenter, randomized, open-label, noninferiority, phase 3 trial.

The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study

SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.

Preoperative short-course radiotherapy followed by consolidation chemotherapy for treatment with locally advanced rectal cancer: a meta-analysis

Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.

Short-Course Radiotherapy Based Total Neoadjuvant Therapy Combined with Toripalimab for Locally Advanced Rectal Cancer: Preliminary Findings from a Randomized, Prospective, Multicenter, Double-Arm, Phase II Trial (TORCH)